CYTOSORBENTS CORPORATION (NASDAQ:CTSO) Files An 8-K Results of Operations and Financial Condition
On January 14, 2020, CytoSorbents Corporation (the “Company”) issued a press release announcing preliminary financial results for the fiscal year ended December 31, 2019. The press release incorporates an open letter to stockholders from the Company’s Chief Executive Officer, Dr. Phillip Chan, discussing the Company’s recent performance and prospects. A copy of the press release is furnished herewith as Exhibit 99.1.*
|Exhibit No.||Exhibit Name|
|99.1||CytoSorbents Corporation Press Release, dated January 14, 2020|
*The information in Item 2.02 of this Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Cytosorbents Corp Exhibit
EX-99.1 2 tm203321d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 CytoSorbents Reports Preliminary 2019 Financial Results and Issues Stockholder Letter Growth accelerated in Q4 2019,…
To view the full exhibit click
About CYTOSORBENTS CORPORATION (NASDAQ:CTSO)
CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company’s purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. The Company’s CytoSorb is an extracorporeal cytokine filter and is designed to reduce the cytokine storm that causes inflammation, organ failure and death in common critical illnesses, such as sepsis, burn injury, trauma, lung injury and pancreatitis. In addition, CytoSorb is used in other inflammatory conditions, such as cardiac surgery and autoimmune disease flares and cancer cachexia. It also has other products under development based upon its blood purification technology, including HemoDefend, ContrastSorb, DrugSorb, BetaSorb and others.